Chemopreventive potential of an ethyl acetate fraction from Curcuma longa is associated with upregulation of p57kip2 and rad9 in the pc-3m prostate cancer cell line

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 3, 2012, Pages 1031-1038

  Rao, K V K ^a   Samikkannu, T ^a   Dakshayani, K B ^a   Zhang, X ^b   Sathaye, S S ^c   Indap, M A ^d   Nair, Madhavan P N ^a  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b USA   (United States)

^c INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^d ACTREC   (India)

Author keywords

Curcuma longa; Ethyl acetate fraction; Invasive ability; Up regulation

Indexed keywords

ANTIOXIDANT; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; PLANT EXTRACT; PROTEIN RAD9;

ARTICLE; CANCER INVASION; CELL PROLIFERATION; CURCUMA; DRUG EFFECT; FRACTIONATION; HUMAN; MALE; METABOLISM; PHYTOTHERAPY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIOXIDANTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMICAL FRACTIONATION; CURCUMA; CYCLIN-DEPENDENT KINASE INHIBITOR P57; HUMANS; MALE; NEOPLASM INVASIVENESS; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC NEOPLASMS;

EID: 84871702905     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.3.1031     Document Type: Article

References (56)

1. Aggarwal BB (2008). The past, present and future of multi-targeted cancer treatment "Naturally": Food for thought. Cancer Lett, 269, 187-8.
2. Aggarwal BB, Bhatt ID, Ichikawa H, et al (2006). Curcumin-Biological and Medicinal Properties, The CRC Press, Boca Raton, FL, ?, 297-368.
3. Aggarwal BB, Kumar A, Bharti AC (2003). Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res, 23, 363-98.
4. Aggarwal BB, Surh YH, Shishodia S (2007). The molecular targets and therapeutics of curcumin in health and diseaseAdvances in Experimental Medicine and Biology, vol. 995, Springer Publication.
5. Aiping Z, Charles XZ, Lieberman HB (2008). Rad9 Has a Functional Role in Human Prostate Carcinogenesis. Cancer Res, 68, 1267-74.
6. Albini A (1998). Tumor and endothelial cell invasion of basement membranes. The Matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res, 4, 230-2.
7. Alpers DH (2008). The potential use of curcumin in management of chronic disease: too good to be true ?. Curr Opin Gastroent, 24, 173-5.
8. American Cancer Society: What are the key statistics about prostate cancer, Cancer Reference Information 2008.
9. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB (2008). Curcumin and cancer: An "old-age" disease with an "age-old" solution. Cancer Lett, 267, 133-64.
10. Anto RJ, George J, Babu KV, Rajasekharan KN, Kuttan R (1996). Antimutagenic and anticarcinogenic activity of natural and synthetic curcuminoids. Mutat Res, 370, 127-31.
11. Bessho T, Sancar A (2000). Human DNA damage checkpoint protein hRAD9 is a 3 to 5 exonuclease. J Biol Chem, 275, 7451-4.
12. Choudhuri PST, Das T, Sa G (2005). Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem, 20, 20059-68.
13. Cunningham B (2001). Assessing differential gene expression. The Scientist, 15, 27-31.
14. Dedhar S, Saulnier R, Nagle R, Overall CM (1993). Specific alterations in the expression of alpha3beta1 and alpha6beta4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin Exp Metastasis, 11, 391-400.
15. Dhillon N, Aggarwal BB, Li L, et al (2006). Phase II trial of curcumin (diferuloylmethane), an NF-jB inhibitor, in patients with advanced pancreatic cancer. J Clin Oncol, 24, 14151-6.
16. Dorai T, Aggarwal BB (2004). Role of chemopreventive agents in cancer therapy. Cancer Lett, 215, 129-40.
17. Duvoix A, Blasius R, Delhalle S, et al (2005). Chemopreventive and therapeutic effects of curcumin. Cancer Lett, 223, 181-90.
18. Garcea G, Berry DP, Jones DJ, et al (2005). Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev, 14, 120-5.
19. Hopkins KM, Auerbach W, Wang XY, et al (2004). Deletion of mouse Rad9 causes abnormal cellular responses to DNA damage, genomic instability, and embryonic lethality. Mol Cell Biol, 16, 7235-48.
20. Hsu CL, Chen YL, Ting HJ (2005). Androgen receptor (AR) NH2- and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth. Mol Endocrinol, 19, 350-61.
21. Jin RJ, Lho Y, Wang Y, et al (2008). Down-regulation of p57Kip2 Induces Prostate Cancer in the Mouse. Cancer Res, 68, 3601-8.
22. Jin RJ, Wang Y, Masumori N, et al (2004). NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res, 64, 5489-95.
23. Komatsu K, Miyashita T, Hang H, et al (2000). Human homologue of S. pombe Rad9 interacts with Bcl-2/Bcl-XL and promotes apoptosis. Nat Cell Biol, 2, 1-6.
24. Krishnan K, Ruffin MT, Brenner DE (1998). Cancer chemoprevention: A new way to treat cancer before it happens. Primary Care, 25, 361-79.
25. Kunnumakkara AB, Anand P, Aggarwal BB (2008). Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett, 269, 199-225.
26. Lee MH, Reynisdottir I, Massague J (1995). Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev, 9, 639-49.
27. Lieberman HB, Hopkins KM, Nass M, Demetrick D, Davey S (1996). A human homolog of the Schizosaccharomyces pombe rad9+ checkpoint control gene. Proc Natl Acad Sci USA, 93, 13890-5.
28. Lieberman HB (2006). Rad9, an evolutionarily conserved gene with multiple functions for preserving genomic integrity. J Cell Biochem, 97, 690-7.
29. Liu E, Wu J, Cao W, et al (2007). Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol, 85, 263-70.
30. Mahudawala DM, Redkar AA, Wagh A, Gladstone B, Rao KVK (1999). Malignant transformation of Syrian hamster embryo (SHE) cells in culture by malachite green: An agent of environmental importance. Indian J Exp Biol, 37, 904-18.
31. Matsuoka S, Edwards MC, Bai C, et al (1995). p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev, 9, 650-62.
32. Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y (1995). Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol, 49, 1165-70.
33. Mukhtar H, Ahmad N (1999). Cancer chemoprevention: future holds in multiple agents. Toxicol Appl Pharmacol, 158, 207-10.
34. Nair HK, Rao KVK, Aalinkeel R, et al (2004). Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol USA, 11, 63-9.
35. Olszanecki R, Jawien J, Gajda M, et al (2005). Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol, 56, 627-35.
36. Panandiker A, Fernandes C, Rao KVK (1992). The cytotoxic properties of malachite green are associated with the increased demethylase, aryl hydrocarbon hydroxylase and lipid peroxidation in primary cultures of Syrian hamster embryo cells. Cancer Lett, 67, 93-101.
37. Panandiker A, Maru GB, Rao KVK (1994). Dose-response effects of malachite green on free radical formation, lipid peroxidation and DNA damage in Syrian hamster embryo cells and their modulation by antioxidants. Carcinogenesis, 15, 2445-8.
38. Park BS, Kim JG, Kim MR, et al (2005). constituents inhibit sortase A and Staphylococcus aureus cell adhesion to fibronectin. J Agric Food Chem, 53, 9005-9.
39. Rafailov S, Cammack S, Stone BA, Katz AE (2007). The role of zyflamend, an herbal anti-inflammatory, as a potential chemopreventive agent against prostate cancer: a case report. Integr Cancer Ther, 6, 74-6.
40. Rao KVK, Schwartz SA, Nair HK, et al (2004). Plant derived products as a source of cellular growth inhibitory phytochemicals on PC-3M, DU-145 and LNCaP prostate cancer cell lines. Curr Sci, 87, 1585-8.
41. Rao KVK, Boukli NM, Samikkannu T, et al (2011). Proteomic profiling and cytotoxic effect of Curcuma longa on prostate cancer. The Open Proteomic J, 4, 1-11.
42. Rock CL (1998). Nutritional factors in cancer chemoprevention. Hematol Oncol Clin North Am, 12, 975-91.
43. Sandur SK, Pandey MK, Sung B, et al (2007). Curcumin, demethoxycurcumin, bisdemothoxycurcumin, tetrahydrocurcumin, and turmerones differentially regulate anti-inflammatory and antiproliferative responses through a ROS-independent mechanism. Carcinogenesis, 8, 1765-73.
44. Samuelsson MKR, Pazirandeh A, Davani B, Okret S (1999). p57kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol Endocrinol, 13, 1811-22.
45. Sharma RA, Euden SA, Platton SL, et al (2004). Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res, 10, 6847-54.
46. Shively CA, Mirkes SJ, Lu NZ, Henderson JA, Bethea CL (2003). Soy and social stress affect serotonin neurotransmission in primates. Pharmacogenomics, 3, 114-21.
47. Syed DN, Khan N, Afaq F, Mukhtar H (2007). Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev, 16, 2193-204.
48. Syed DN, Suh Y, Afaq F, Mukhtar H (2008). Dietary agents for chemoprevention of prostate cancer. Cancer Lett, 265, 167-76.
49. Thangapazham RL, Sharma A, Maheshwari RK (2006). Multiple molecular targets in cancer chemoprevention by curcumin. AAPSJ, 8, 443-9.
50. Tsugu A, Sakai K, Dirks PB, et al (2000). Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. Am J Pathol, 57, 919-32.
51. Vecchia CL, Tavani A (1998). Fruits and vegetables, and human cancer. Eur J Cancer, 7, 3-8.
52. Wang L, Hsu CL, Ni J (2004). Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells. Mol Cell Biol, 24, 2202-13.
53. Wattenberg LW (1997). An overview of chemoprevention: current status and future prospects. Proc Soc Exp Biol Med, 216, 133-41.
54. Williams K, Fernandez S, Stien X, et al (2005). Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate, 63, 369-84.
55. Yang F, Lim GP, Begum AN, et al (2005). Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem, 280, 5892-901.
56. Zhang P, Liegeois NJ, Wong C, et al (1997). Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature, 387, 151-8